Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +0.47% 53.75p 53.75p 55.75p 54.75p 53.75p 54.75p 46,609.00 13:56:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.1 -4.5 -4.4 - 71.23

Immupharma Share Discussion Threads

Showing 7626 to 7648 of 7650 messages
Chat Pages: 306  305  304  303  302  301  300  299  298  297  296  295  Older
DateSubjectAuthorDiscuss
28/4/2017
12:48
Thanks Water - interesting. A really terrible malady, if for no other reason lets hope P140 goes well.
colsmith
28/4/2017
12:45
Nice research waterloo01
sicilian_kan
28/4/2017
12:20
htTps://www.ncbi.nlm.nih.gov/pubmed/28367820 [Autophagy, autoimmunity and autoimmune diseases]. [Article in French] Muller S1. Author information Abstract Autoimmune diseases such as systemic lupus, are the consequence of immunity directed against the organism itself. The immune system abnormally recognizes self-components as foreign and produces antibodies targeting normal cells and tissues. We and others have discovered a number of failures affecting autophagy pathways in the lymphocytes of model mice and patients with lupus. While the current treatments are mainly based on immunosuppressive drugs that can lead to important side effects, the synthetic phosphopeptide P140/Lupuzor, which targets chaperone-mediated autophagy and displays no side effects, holds a lot of promise as a drug candidate. P140, which is currently evaluated in a phase III clinical trial, targets chaperone-mediated autophagy that is hyperactivated in lupus mice, and reduces antigenic peptides presentation to autoreactive helper T cells. Remarkably, we showed in lupus mice that upon treatment with P140, a number of immunological abnormalities affecting the pool of T and B cells as well as many biological and clinical features no longer occur. © 2017 médecine/sciences – Inserm.
waterloo01
28/4/2017
10:52
htTp://www.bfmtv.com/sante/un-traitement-prometteur-pour-soigner-le-lupus-1151988.html (use google translate) 80,000 - 100,000 lupus patients in France alone. Patients with systemic lupus erythematosus (SLE) may soon benefit from a new kind of treatment. The French immunologist Sylviane Muller, who is competing for the "European Inventor's Award", has found a way to relieve the symptoms but also to stop the progression of the disease. "Sylviane Muller's invention is a breakthrough in the treatment of this incurable autoimmune disease, which affects the quality of life of millions of people. For the first time, they can expect targeted treatment that can literally extinguish Lupus , "said EPO President Benoît Battistelli at the announcement of the finalists.
waterloo01
27/4/2017
15:07
Thanks PDT, encouraging.
homebrewruss
27/4/2017
14:53
"The global SLE and LN market is expected to display a healthy CAGR of 10.6% between 2015 and 2025 for the revenue generation to reach US$3.2 bn by 2025 increasing from US$1.2 bn in 2015. The U.S. is expected to contribute substantially to the growth of the global market. This is due to increased diagnosis of prevalence of SLE and LN and the introduction of three first-in-class pipeline drugs, namely anifrolumab, lupuzor, and orencia." Quote From; hTTps://www.medgadget.com/2017/04/global-systemic-lupus-erythematosus-and-lupus-nephritis-market-to-display-10-6-cagr-from-2015-to-2025.html
pdt
27/4/2017
11:07
This board is a well run and informative one ( as are all of SK's boards ), with some very knowledgeable posters. However, when new posters arrive and make positive contributions, such as hottingup did here a while back, I would expect a more welcoming reaction than " You don't say ". This is not an exclusive club.
luminoso
27/4/2017
10:48
Carnivale, By my calculations Lanstead only have 5 more payments (of 18) due under the subscription agreement. Last TR1 showed they were holding just over 7.4 m shares and would assume that the potential upside of a long position would outweigh any short term benefit from lower monthly payments. Of course, they are already sitting on a substantial profit from the vendor placing. I agree with your comments on how any Lanstead sells are likely to be handled by Northland. The above, together with the relatively low volumes is why I wonder whether we are just seeing just a few retail investors taking profit until the next bit of news when they'll be back.
bermudashorts
27/4/2017
10:25
PJ1 - it won't be bang up to date but should be more recent that the Y/E
bermudashorts
27/4/2017
10:17
bermudashorts-Won't the AR show significant shareholding at year end (December) and therefore will probably be inaccurate compared to today?
pj 1
27/4/2017
10:04
thanks Bermuda regarding Landstead, you are right payments under the original agreement are due to restart in May, but in the past , whilst they have met all the scheduled payments , they have not sold the stock , including the last 6 months worth of "accelerated " funding .. Of course nothing prevents them from resuming sales , but i remain of the opinion that they will seek Northland and the company's help to match a buyers need with their sale as the have done so far .
carnivale
27/4/2017
09:58
Carnivale, From memory Lanstead's payments to IMM resume in May, it's possible that they are selling in advance of that, but volumes are still pretty low. Could simply be that we are seeing typical bio drift in between inflection points. The annual report is due very shortly and list of significant holders may reveal whether Lanstead have sold any. As for the symposium - haven't heard any further.
bermudashorts
27/4/2017
09:28
carnival, "trolls or whatever one calls disruptive posters are best ignored" That path leads to echo chambers. Labelling those who post dissenting views as "trolls" or "disruptive posters" will mean that when someone genuinely highlights a problem you will have your head in the sand and won't hear their voice. Because you've long ago decided to only listen to the views of people that you agree with. JakNife
jaknife
27/4/2017
09:21
trolls, or whatever one calls disruptive posters, are best ignored , fullstops What I would like anyone with any idea on the subject to confirm is that i did not dream the idea tat we were going to get a symposium circa end of April .. Silence on the matter might suggest a postponement or a cancellation , and if so , any idea what might be the reason behind it ? Also it appears that we have an ongoing seller ..and so far the obvious candidate (Landstead) appears to hold fast ..if so who might the ongoing seller be, and why ? Of course none of the above change anything as to the risk/reward ratio of the proposition , but a) speculating on it is a damn better than giving trolls some air to breath b) a date for the symposium might keep hopes alive of further progress on the potential applications using the same MOA as lupuzor for Lupus Of course , by far the biggest news we could hope for in coming weeks/month is a reasonable licensing deal being agreed upon, as it would allow faster development of the rest of the pipeline (and in the process perhaps attract new Institutions looking for more than a 1 trick pony ) , and it would allow both the company and shareholders to deaisk ahead of results ... happy trolling
carnivale
27/4/2017
08:52
Ah well that is the issue.You have what you want and it is a feeling shared by many but unfortunately as this is a free bulletin board, with little to no censorship policy applied, we can't demand that everyone follow our expectations.The best thing is to just follow your own rules and not get too worked up if others fail to live by the same standards.
longshanks
27/4/2017
08:48
I think it is quite sweet that Beeks has the time and inclination to come on here and moan about a company he is not invested in based on the fact that one idiot spammed some other boards. If he bothered to poke around he would find a great deal of information, a board which is generally pretty informative, and of course an Investment case which is as good as anything I have ever seen on AIM.
qazwsxedc69
27/4/2017
08:40
longshanks, really don't give a monkey's why anyone is here and whether they post positively or negatively about IMM, just so long as it's about IMM. This used to be one of the few boards where knowledgeable and well researched posters could openly discuss both positives and negatives of a stock (and let's face it we've had plenty of negatives in the past to discuss).
bermudashorts
27/4/2017
07:44
4th rule - people only post negatively to "get in cheaper".
beeks of arabia
27/4/2017
07:32
Why now are we getting trolls?Hmmm....perhaps some II's want a cheaper entry point and a larger piece of the action....Beeks, do some research quietly on this forum and from other sources and if you do comment, comment without the attitude. And if you do feel IMM isn't for you then shut the door quietly on your way out!
hamila01
27/4/2017
07:30
What has happened to this board?
bermudashorts
27/4/2017
07:19
If your not interested in this share, why are you here, go and play in your sand pit,
barriew
26/4/2017
22:38
3rd rule of investing, be wary of threads where positive posts are upvoted whilst neutral of negative posts receive nothing.....
beeks of arabia
26/4/2017
21:27
That actually comes under the first one, however it's your money.Price is down 10รท since the imm emissaries were sent out to troll....
beeks of arabia
Chat Pages: 306  305  304  303  302  301  300  299  298  297  296  295  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170428 14:06:01